Latest Share Chat

IN BRIEF: Hemogenyx To Take Next Steps In Developing Virus Treatment

Mon, 15th Jun 2020 17:54

Hemogenyx Pharmaceuticals PLC - London-based biotechnology firm - Continuing development of Covid-19 medication. Says subsidiary Immugenyx LLC will take cells from blood samples of former Covid-19 sufferers and transplant them into advanced peripheral blood hematopoietic chimera or advanced humanised mice. Hemogenyx says process will allow scientists to recreate virus antibodies.

Current stock price: 5.65 pence

Year-to-date change: up almost threefold from 1.93p on January 2

By Eric Cunha; ericcunha@alliancenews.com

Related Shares

More News

25 Apr 2024 12:19

EARNINGS: LSL starts 2024 "strongly"; Focusrite maintains payout

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately report...

29 Feb 2024 14:04

Hemogenyx Pharmaceuticals raises money for leukaemia treatment

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Thursday said it has raised GBP3.3 million through a placing.

16 Feb 2024 11:27

Hemogenyx shares rise on potential for CBR to treat brain diseases

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Friday said research has shown that its proprietary chimeric bait receptor can be delivered into th...

14 Feb 2024 10:14

Hemogenyx says CBR can be used intranasally to treat viral infections

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Wednesday said its chimeric bait receptor can be delivered intranasally in the form of messenger RN...

9 Feb 2024 10:00

IN BRIEF: Hemogenyx shares surge as FDA lifts Hemo-Car-T trial hold

Hemogenyx Pharmaceuticals PLC - London-based biopharmaceutical company focused on treatments for deadly blood diseases - US Food & Drug Administration...